Blog
RSS FeedPosted by Michael Wonder on 15 Oct 2021
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
15 October 2021 - The UK NICE has recommended BMS' Opdivo (nivolumab) as a treatment option for certain resected oesophageal ...
Posted by Michael Wonder on 06 Oct 2021
NICE terminates another appraisal for a Roche medicine
6 October 2021 - The sixth termination of the appraisal of a Roche medicine. ...
Posted by Michael Wonder on 05 Oct 2021
Venetoclax comes close to gaining support from NICE
4 October 2021 - A proposal from AbbVie for a Cancer Drugs Fund listing may get it over the line. ...
Posted by Michael Wonder on 30 Sep 2021
People with advanced or metastatic urothelial cancer to get life-extending treatment
30 September 2021 - Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for ...
Posted by Michael Wonder on 17 Sep 2021
Keytruda made available on the NHS for certain oesophageal cancer patients
17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...
Posted by Michael Wonder on 15 Sep 2021
NICE backs Opdivo for head and neck cancer
15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 27 Aug 2021
NICE ‘no’ for Janssen’s Darzalex combo
27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, ...
Posted by Michael Wonder on 25 Aug 2021
NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer
25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 12 Aug 2021
NICE draft guidance recommends abemaciclib for advanced breast cancer
12 August 2021 - NICE has today published draft guidance which recommends a twice daily pill abemaciclib (Verzenios; Eli Lilly) as ...
Posted by Michael Wonder on 22 Jul 2021
Patients with rare bile duct cancer set to benefit from life extending treatment
22 July 2021 - Some people who have a rare form of bile duct cancer are set to benefit from life-extending ...
Posted by Michael Wonder on 16 Jul 2021
Ledaga recommended by NICE for rare type of lymphoma
16 July 2021 - NICE has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that ...
Posted by Michael Wonder on 16 Jul 2021
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
16 July 2021 - NICE has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the ...